Agenus surges on study pivot; Apnimed lines up an IPO
Agenus surges on study pivot; Apnimed lines up an IPO
Agenus
Private
Agenus is a clinical-stage immuno-oncology company developing immune checkpoint antibodies, cancer vaccines, and adjuvants. Lead programs include botensilimab (a next-gen CTLA-4 antibody) and balstilimab (anti-PD-1). The company's pipeline targets colorectal cancer (CRC), pancreatic cancer, and other solid tumors. Agenus was acquired by GC Cell Corporation in 2024 and is now a private company.
Company Info
Sector:Immuno-oncology
Headquarters:Lexington, Massachusetts, USA
Founded:1994
Website:www.agenusbio.com
Funding Round:See funding history at company website
Total Funding:See company disclosures
Funding & Investor Relations
IPO Outlook / Plans
TBD
Recent News
Agenus scraps ph. 3 colorectal study to narrow focus to colon
Agenus has scrapped a phase 3 study of its combo therapy in colorectal cancer after just three months in order to go all-in on colon cancer. The biotech launched the late-stage Battman study in April to evaluate a combination of its CTLA-4 inhibitor botensilimab and an anti-PD-1 antibody balstilimab in unresectable microsatellite stable (MSS) metastatic colorectal cancer (mCRC). The aim was to enroll 830 patients across Canada, France, Australia and New Zealand.
Leadership Team
TBD
CEO
Careers & Job Openings